Examining a New Treatment for Advanced Solid Tumors

Recruiting · Phase 1 · Carcinoma, Non-Small Cell Lung and related conditions · 19 states

Check if I qualify View on ClinicalTrials.gov

About this trial

This trial looks at a new medicine called sigvotatug vedotin. It is being tested alone and with pembrolizumab, and sometimes with chemotherapy. The goal is to see how safe the medicine is and if it can help treat different solid tumors. The study has four parts, focusing on finding the right dose and testing combinations with other medicines.

The trial's ID number is NCT04389632. It is a Phase 1 study, which means it is looking at how well the treatment works and its safety. The trial is regulated by the FDA and aims to include about 1,006 participants.

Who can join

Adults aged 18 and older can join if they have certain advanced solid tumors. They should have tumors that cannot be removed by surgery or have spread to other parts of the body. Some parts of the study have specific requirements about previous treatments. The trial team will check if you qualify before you can join.

Conditions

Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Ovarian Neoplasms, Cutaneous Squamous Cell Cancer, Exocrine Pancreatic Adenocarcinoma, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Stomach Neoplasms

Age group

Adult, Older adult

Sex

All sexes

The study team makes the final call on eligibility.

What happens in the study

Participants will be placed into different groups based on the study part. In Part A, they will receive sigvotatug vedotin alone. Part B also uses this medicine alone. In Parts C and D, participants will receive sigvotatug vedotin with pembrolizumab, and possibly with carboplatin or cisplatin, depending on their specific situation.